Skip to main content

Table 3 Aminoacid substitutions in HCV NS3 protease region associated with resistance to DAAsa in treatment-naïve patients

From: Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C

Rb Pc Dd Me Drug G 1b (n = 11) G 2c (n = 11) G 4d (n = 6)
NS3 16 C S ACH806 *C/R(9) *A(100) *T(100)
NS3 36 V A,M,G,L Telaprevir, Boceprevir *V(100) L(100)f L(100)f
NS3 54 T A,S Telaprevir, Boceprevir
NS3 155 R K,T,I,MG,L,S,Q Telaprevir, Boceprevir
NS3 156 A S,T,V,I Telaprevir, Boceprevir
NS3 168 D Q,A,V,E,T TMC435,R7227,MK7009, BI201335, BILN2061
NS3 175 M L Telaprevir *M(100) L(100)f L(100)f
  1. a direct acting antiviral agents
  2. Rb, Region; Pc,Position aa; Dd,Dominant aa; Me, Mutant aa; (Lopez-Labrador, 2008; Lentz, 2010; Kieffer [15], Halfon [13], Kuntzen [19])
  3. *Percentage of sequences with substitutions
  4. •The dominant residue is found in 100 % of analyzed sequences for each genotype
  5. f Substitution found is associated with resistance in genotype 1b